Welcome to our dedicated page for NOVO NORDISK A S SEC filings (Ticker: NONOF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NOVO NORDISK A S's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NOVO NORDISK A S's regulatory disclosures and financial reporting.
Novo Nordisk will acquire Akero Therapeutics for $54 per share in cash, representing total consideration of about $4.7B, plus a contingent value right of $6 per share (about $0.5B) on closing. The deal adds Akero's FGF21 analogue efruxifermin (EFX), described as the only therapy to show significant fibrosis regression in phase 2 patients with compensated cirrhosis (F4).
EFX is positioned to treat metabolic dysfunction-associated steatohepatitis (MASH), a comorbidity closely linked to diabetes and obesity; the filing notes >40% of MASH patients have type 2 diabetes and >80% are overweight or living with obesity. Novo Nordisk highlights ongoing programs including SYNCHRONY Histology, SYNCHRONY Outcomes, and SYNCHRONY Real-World to evaluate EFX across F1–F4 disease stages, with once-weekly subcutaneous dosing reported as generally well tolerated in trials to date.